Table 3B.
Vaccine effectiveness for cross-protective types HPV31, HPV33 and HPV45 after 3- and 2-dose schedules compared with no vaccination after 2vHPV and 4vHPV vaccination.
| Study | Vaccine | Outcome | Proportion 3-dose (+95% CI) | Proportion 2-dose (+95% CI) | VE 3-dose (+95% CI) | VE 2-dose (+95% CI) | Proportion Two-dose (0,1 month) (+95% CI) | Proportion Two-dose (0,6 month) (+95% CI) | VE 3-dose (0,1 month) (+95% CI) | VE 3-dose (0,6 month) (+95% CI) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kavanagh46 | 2vHPV | HPV31/33/45 prevalence | 6.8% (5.5–8.5%) | 7.5% (3.9–14.2%) | 85% 1 (81–88%) | 83% 1 (66–91%) | |||||
| Kreimer – Costa Rica Vaccine Trial/ PATRICIA trial (modified total vaccinated cohort)45 | 2vHPV | Incident one-time detection of HPV31/33/45 | Rate per 100 PY 1.65 (1.53–1.78) | Rate per 100 PY 2.21 (1.68–2.85) | 59.7% 1 (56.0–63.0%) | 37.7% 1 (12.4–55.9%) | |||||
| Incident detection of HPV31/33/45 that persisted at least 6 months | Rate per 100 PY 0.61 (0.54–0.69) | Rate per 100 PY 0.71 (0.43–1.09) | 60.1% 1 (54.0–65.4%) | 30.7% 1 (-27.9–63.0%) | Rate per 100 PY 2.76 (1.96–3.78) | Rate per 100 PY 3.07 (2.21–4.18) | 10% (−42–43%) | 68% (27–87%) | |||
| Incident detection of HPV31/33/45 that persisted at least 12 months | Rate per 100 PY 0.40 (0.34–0.46) | Rate per 100 PY 0.43 (0.23–0.74) | 54.9% 1 (46.2–62.3%) | 7.6% 1 (−118 - 61%) | |||||||
| Sankaranarayanan33 | 4vHPV | Incident detection HPV31/33/45 | 6.0% (4.1–8.3%) | 4.6% (3.2–6.4%) | 4.9% (3.3–7.2%) |
PY, person years. 1Both vaccinated groups were compared to their own control group, composed of participants randomized for the control vaccine (Hepatitis A) who had received an equal number of doses.